# Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer

> **NCT07298577** · NA · ENROLLING_BY_INVITATION · sponsor: **Siriraj Hospital** · enrollment: 2100 (estimated)

## Conditions studied

- Liver Cirrhosis
- Hepatitis B, Chronic
- Hepatitis C, Chronic
- Carcinoma, Hepatocellular

## Interventions

- **DIAGNOSTIC_TEST:** PIVKA-II and GAAD score calculation

## Key facts

- **NCT ID:** NCT07298577
- **Lead sponsor:** Siriraj Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-02-02
- **Primary completion:** 2029-02-02
- **Final completion:** 2030-07-31
- **Target enrollment:** 2100 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298577, "Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07298577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*